Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Epigenetic alternations concern heritable yet reversible changes in histone or DNA
modifications that regulate gene activity beyond the underlying sequence. Epigenetic …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Medical castration that interferes with androgen receptor (AR) function is the principal
treatment for advanced prostate cancer. However, clinical progression is universal, and …

Highlights•Patients who receive antiandrogen treatments are more likely to develop
CRPC.•A genomic landscape study has identified aberrant epigenetic events in CRPC and …

The acceptance of new crop varieties by consumers is contingent on the presence of
consumer-preferred traits, which include sensory attributes, nutritional value, industrial …

Cancer was thought to be caused solely by genetic mutations in oncogenes and tumor
suppressor genes. In the last 35 years, however, epigenetic changes have been …

Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of
multiple genes including MYC, and supraphysiological androgen is effective in some …

Lysine-specific demethylase 1A (LSD1, also named KDM1A) is a demethylase that can
remove methyl groups from histones H3K4me1/2 and H3K9me1/2. It is aberrantly expressed …